Definition of treatment goals for moderate to severe psoriasis: a European consensus

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F11%3A00002849" target="_blank" >RIV/00216208:11120/11:00002849 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/11:#0000290

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00403-010-1080-1" target="_blank" >http://dx.doi.org/10.1007/s00403-010-1080-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00403-010-1080-1" target="_blank" >10.1007/s00403-010-1080-1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Popis výsledku v původním jazyce

Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem, the consensus programme was performed to define goals for treatment of plaque psoriasis with systemic therapy and to improve patient care. An expert consensusmeeting and a collaborative Delphi procedure were carried out. Nineteen dermatologists from different European countries met for a face-to-face discussion and defined items through a four-round Delphi process. Severity of plaque psoriasis was graded intomild and moderate to severe disease. Mild disease was defined as body surface area (BSA) </=10 and psoriasis area and severity index (PASI) </=10 and dermatology life quality index (DLQI) </=10 and moderate to severe psoriasis as (BSA > 10 or PASI > 10)and DLQI > 10. Special clinical situations may change mild psoriasis to moderate to severe including involvement of visible areas or severe nail involvement. For systemic therapy of plaque psoriasis two treatment phases were defined: (

Název v anglickém jazyce

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Popis výsledku anglicky

Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem, the consensus programme was performed to define goals for treatment of plaque psoriasis with systemic therapy and to improve patient care. An expert consensusmeeting and a collaborative Delphi procedure were carried out. Nineteen dermatologists from different European countries met for a face-to-face discussion and defined items through a four-round Delphi process. Severity of plaque psoriasis was graded intomild and moderate to severe disease. Mild disease was defined as body surface area (BSA) </=10 and psoriasis area and severity index (PASI) </=10 and dermatology life quality index (DLQI) </=10 and moderate to severe psoriasis as (BSA > 10 or PASI > 10)and DLQI > 10. Special clinical situations may change mild psoriasis to moderate to severe including involvement of visible areas or severe nail involvement. For systemic therapy of plaque psoriasis two treatment phases were defined: (

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FO - Dermatovenerologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Archives of Dermatological Research

ISSN

0340-3696

e-ISSN

—

Svazek periodika

303

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

1-10

Kód UT WoS článku

000287660200001

EID výsledku v databázi Scopus

—